S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
Free Trial
OTCMKTS:ISCNF

Isracann Biosciences (ISCNF) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)
Free ISCNF Stock Alerts
Compare
Today's Range
N/A
50-Day Range
$0.0001
▼
$0.0110
52-Week Range
N/A
Volume
666 shs
Average Volume
115,775 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartShort Interest
ISCNF stock logo

About Isracann Biosciences Stock (OTCMKTS:ISCNF)

Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. The company also develops cultivation facilities. It exports its products to Germany. The company was formerly known as Atlas Blockchain Group Inc. and changed its name to Isracann Biosciences Inc. in October 2019. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada.

ISCNF Stock News Headlines

April 6, 2023 | finance.yahoo.com
IIROC Trading Halt - IPOT
April 6, 2023 | finance.yahoo.com
Isracann Biosciences Inc. (ISCNF)
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
October 25, 2022 | seekingalpha.com
ISCNF Isracann Biosciences Inc.
October 13, 2022 | finance.yahoo.com
Isracann Biosciences Provides Bi-Weekly Default Status Report
September 28, 2022 | finance.yahoo.com
Isracann Bioscience Facilitated Genetics Arrive in Israel
September 14, 2022 | benzinga.com
Isracann Bioscience Facilitates Cannabis Genetics Shipment To Israel
September 1, 2022 | msn.com
Isracann's Praesidio Expands Its Natural Health Products Distribution Network: Inks Deal With Pure Integrative Pharmacy
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
September 1, 2022 | financialpost.com
Praesidio signs distribution agreement with Pure Integrative Pharmacy
August 25, 2022 | proactiveinvestors.com
Isracann Biosciences adds Super Bowl MVP Mark Rypien to company advisory board
August 23, 2022 | finance.yahoo.com
Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board
August 3, 2022 | msn.com
Cannabis Company Isracann Biosciences Raises $234K In The First Tranche Of Private Placement
August 3, 2022 | finance.yahoo.com
Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
May 21, 2022 | msn.com
Isracann Biosciences' Subsidiary Praesidio Health Submits NPNs To Health Canada
May 19, 2022 | finance.yahoo.com
Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada
April 15, 2022 | financialpost.com
Isracann Biosciences Renews Leadership to Meet Changing Demands
April 14, 2022 | seekingalpha.com
Isracann Biosciences acquires Praesidio Health and appoints products officers
April 14, 2022 | msn.com
Isracann Biosciences Acquires Praesidio Health And Appoints Natural Health Products Officers
April 13, 2022 | finance.yahoo.com
Isracann Biosciences Acquires Natural Health Medicine Developer and Appoints Natural Health Products Officers
March 28, 2022 | msn.com
Isracann Biosciences Signs Definitive Agreement To Acquire Praesidio Health For $3.18M
March 28, 2022 | seekingalpha.com
Isracann Biosciences to acquire Canadian natural health medicine developer
March 28, 2022 | finance.yahoo.com
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer
February 24, 2022 | finance.yahoo.com
UPDATE - Isracann Signs LOI to Acquire Natural Health Medicine Developer
February 23, 2022 | seekingalpha.com
Isracann to acquire natural health medicine developer
February 23, 2022 | msn.com
Isracann To Acquire Natural Health Medicine Developer Praesidio Health For $3.14M
February 23, 2022 | financialpost.com
Isracann Signs LOI to Acquire Natural Health Medicine Developer
See More Headlines
Receive ISCNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Isracann Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:ISCNF
CUSIP
N/A
CIK
N/A
Web
www.isracann.com
Phone
604-394-2551
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

ISCNF Stock Analysis - Frequently Asked Questions

How do I buy shares of Isracann Biosciences?

Shares of ISCNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ISCNF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press